About Nuclear receptor subfamily 4 group A member 3
Nuclear receptor subfamily 4 group A member 3 (NR4A3) is a protein
from Homo sapiens identified by UniProt accession
Q92570, 626 residues long.
MolForge cross-references it against 0 known binders and
290 disease associations.
Target properties
| Protein name | Nuclear receptor subfamily 4 group A member 3 |
|---|
| UniProt accession | Q92570 |
|---|
| Gene | NR4A3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 626 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92570-F1 | alphafold | PREDICTED | 64.22 | — |
Amino-acid sequence (626 residues)
MPCVQAQYSP SPPGSSYAAQ TYSSEYTTEI MNPDYTKLTM DLGSTEITAT ATTSLPSIST FVEGYSSNYE LKPSCVYQMQ RPLIKVEEGR APSYHHHHHH HHHHHHHHQQ QHQQPSIPPA SSPEDEVLPS TSMYFKQSPP STPTTPAFPP QAGALWDEAL PSAPGCIAPG PLLDPPMKAV PTVAGARFPL FHFKPSPPHP PAPSPAGGHH LGYDPTAAAA LSLPLGAAAA AGSQAAALES HPYGLPLAKR AAPLAFPPLG LTPSPTASSL LGESPSLPSP PSRSSSSGEG TCAVCGDNAA CQHYGVRTCE GCKGFFKRTV QKNAKYVCLA NKNCPVDKRR RNRCQYCRFQ KCLSVGMVKE VVRTDSLKGR RGRLPSKPKS PLQQEPSQPS PPSPPICMMN ALVRALTDST PRDLDYSRYC PTDQAAAGTD AEHVQQFYNL LTASIDVSRS WAEKIPGFTD LPKEDQTLLI ESAFLELFVL RLSIRSNTAE DKFVFCNGLV LHRLQCLRGF GEWLDSIKDF SLNLQSLNLD IQALACLSAL SMITERHGLK EPKRVEELCN KITSSLKDHQ SKGQALEPTE SKVLGALVEL RKICTLGLQR IFYLKLEDLV SPPSIIDKLF LDTLPF
Explore Nuclear receptor subfamily 4 group A member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets